This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
STAR AF II was a randomized, parallel-group treatment study evaluating three catheter ablation strategies in patients with atrial fibrillation.
| Feature | STAR AF II |
|---|---|
| NCT ID | NCT01203748 |
| Status | Completed |
| Condition | Atrial Fibrillation |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Single |
| Primary purpose | Treatment |
| Lead sponsor | Abbott Medical Devices |
2. Clinical Question
Population
Patients with atrial fibrillation enrolled in a randomized ablation study.
Intervention
Additional ablation strategies combined with pulmonary vein isolation.
Comparator
Pulmonary vein isolation alone.
Primary question
Does adding additional ablation strategies improve freedom from documented atrial fibrillation?
3. Trial Design
Randomize
589 patients
Assign
3 treatment arms
Perform
Ablation procedures
Follow
18 months
Assess
AF freedom
PVI + Lines ablation
PVI
PVI + CFE ablation
4. Endpoints
| Endpoint | Definition | Time frame |
|---|---|---|
| Freedom from AF | Freedom from documented AF episodes >30 seconds after one or two ablation procedures with/without antiarrhythmic medications. | 18 months |
5. Planned Analysis
The registry identifies freedom from atrial fibrillation as the primary endpoint. No formal statistical analyses were posted to ClinicalTrials.gov.
Time-to-event and binary outcome considerations
Freedom from documented AF is commonly summarized as the proportion of participants meeting the success definition by a specified follow-up period. Depending on the prespecified statistical analysis plan, time-to-event methods may also be considered when recurrence timing and censoring are incorporated.
6. Statistical Methodology
Randomized treatment comparison
Randomization creates the framework for comparing ablation strategies while reducing systematic differences between treatment groups. The treatment groups are interpreted according to their randomized assignments.
Endpoint definition matters
The primary endpoint definition specifies both the event threshold and the assessment window. AF episodes longer than 30 seconds are included in the registry definition, making endpoint classification dependent on documented rhythm monitoring.
Censoring and follow-up
For outcomes involving recurrence over time, statistical analysis must account for participants who have incomplete observation periods. Censoring assumptions affect interpretation of estimated event-free outcomes.
7. Statistical Methods Explained
Why does the endpoint specify AF episodes longer than 30 seconds?
A prespecified duration threshold creates a consistent definition of recurrence. Without a fixed definition, comparisons between treatment groups can be affected by differences in event classification.
Why compare PVI alone with additional ablation strategies?
The randomized design allows investigators to evaluate whether additional procedural components change the measured outcome relative to a simpler ablation approach.
Why is the 18-month time frame important?
The follow-up period defines when the primary endpoint is evaluated. Longer or shorter observation windows can answer different clinical questions.
Why are multiple arms statistically important?
Three treatment groups create multiple pairwise comparisons. The interpretation of those comparisons depends on the prespecified statistical analysis plan and any adjustment for multiplicity.
8. Limitations
- Registry reporting: The ClinicalTrials.gov record does not report posted statistical analyses for the primary endpoint.
- Endpoint complexity: AF recurrence depends on documented episodes and follow-up assessment procedures.
- Multiple comparisons: A three-arm randomized study requires careful interpretation of comparisons among treatment groups.
- Procedure-specific effects: Differences between ablation strategies include procedural components as well as treatment assignment.
9. Why This Trial Matters Statistically
| Concept | How it appears in STAR AF II |
|---|---|
| Randomization | Three-arm randomized comparison |
| Multiple treatment groups | Comparison of different ablation strategies |
| Composite procedural decisions | Different combinations of ablation approaches |
| Endpoint definition | Freedom from documented AF episodes >30 seconds |
| Follow-up window | 18-month primary endpoint assessment |